Introduction: The Growing Threat of Counterfeit Medicines
Counterfeit and falsified medicines remain a critical global health concern, exposing patients to products that may contain incorrect ingredients, wrong dosages, contaminants, or no active substance at all. In response, the European Union introduced the Falsified Medicines Directive (FMD) to safeguard the integrity of the legal medicines supply chain and ensure that only authentic, safe, and verified products reach patients. The directive, fully in force for safety features since February 2019, has transformed how medicines are packaged, tracked, and verified across Europe.
What Is the Falsified Medicines Directive (FMD)?
The Falsified Medicines Directive (Directive 2011/62/EU) was introduced by the European Commission to combat the growing issue of falsified medicines entering legitimate supply chains.The directive establishes clear regulatory requirements for the manufacture, packaging, and verification of prescription medicines prior to their distribution to pharmacies and patients.
Key Objectives of the FMD
- Prevent falsified medicines from entering legal supply chain.
- Increase transparency and traceability across the pharmaceutical distribution network.
- Strengthen patient and healthcare professional confidence in the authenticity of medicines dispensed.
Key Requirements of the FMD
The FMD mandates several safety and traceability features that every pharmaceutical company must comply with.
1. Serialisation
Every eligible pack of prescription medicine must carry a unique identifier encoded in a 2D Data Matrix code. This typically includes:
- Product code
- Randomised serial number
- Batch (lot) number
- Expiry date
The unique identifier is uploaded to the central EU hub and connected national repositories, allowing stakeholders to verify and decommission each individual pack at any point in the supply chain.
2. Tamper-Proof Packaging
Medicines must include anti-tampering devices or seals to indicate whether a product has been opened or altered after packaging. This ensures the product's integrity from manufacturer to patient.
3. Data Exchange and Verification
Manufacturers and Marketing Authorisation Holders (MAHs) must upload unique identifier data to the European Medicines Verification System (EMVS), which consists of the EU hub and connected National Medicines Verification Systems (NMVS). Wholesalers, pharmacies, and other authorised dispensers scan packs to:
- Verify authenticity by checking the status of the unique identifier.
- Decommission the pack (e.g. “supplied”) at the point of dispensing to patients.
Together, these measures create an end-to-end verification framework that detects falsified, duplicated, or diverted packs before they can be given to patients.
How the FMD Protects Patients
The FMD has brought significant safety and transparency improvements across the European pharmaceutical supply chain.
- Unique identifiers and ATDs make it far harder for falsified medicines to penetrate legitimate channels undetected.
- Supply chain transparency: Each pack's journey from manufacturer to dispenser is traceable through EMVS and NMVS, supporting rapid investigation of incidents.
- Trust in medicines: Healthcare professionals and patients benefit from a system designed to confirm that dispensed packs are genuine, correctly packaged, and not previously supplied or recalled.
The Role of Technology in FMD Compliance
Meeting Falsified Medicines Directive compliance requirements would be impossible without advanced technological support.
Modern pharmaceutical serialisation and drug traceability solutions enable companies to automate and streamline the generation, management, and transmission of serialised data. These systems offer:
- Automate serial number generation, allocation, and lifecycle management.
- Integrate serialisation with packaging lines, printers, and vision systems.
- Secure data transmission to national and EU verification databases.
- Maintain audit-ready records, exception handling workflows, and real-time monitoring dashboards.
By adopting digital traceability platforms, pharmaceutical manufacturers can maintain regulatory compliance while improving operational efficiency and visibility across global supply chains.
How Scan Plus Supports FMD Compliance
Scan Plus provides end-to-end serialisation and traceability solutions specifically designed for pharmaceutical manufacturers, MAHs, CMOs, and distributors operating under FMD and other global serialisation mandates.
The platform helps organisations maintain full control over product identification, data flows, and regulatory reporting while integrating with existing systems and partners.
Key Capabilities of Scan Plus
- Comprehensive Serialisation Management: Manage MAHs, CMOs, products, batches, and serial numbers within a single, unified platform.
- Flexible Data Handling: Support for Direct Access (DA) files, shipment files, and end-of-batch reporting formats.
- Seamless System IntegrationCompatibility with Topia EU-Serialisation for smooth data exchange and verification.
- Enhanced Supply Chain SecurityProtects against falsified entries by validating serial data at every stage.
- Customised Onboarding and Support: Enables quick implementation for new CMO partners and integration within existing operations.
By implementing Scan Plus, organisations can sustain EU FMD compliance, extend to other market serialisation regimes, and gain clearer visibility of pack-level movements across their global supply chains.
Why FMD Compliance Is Essential for Patient Safety
Compliance with the Falsified Medicines Directive is more than a regulatory requirement; it is a direct commitment to patient protection and product stewardship.
Through serialisation, tamper-evident packaging, and EMVS-based verification, the directive ensures that every covered pack reaching a patient has passed authenticity checks and cannot be legitimately reused or reintroduced once dispensed. Platforms like Scan Plus make it possible for pharmaceutical companies to meet these obligations efficiently, reducing operational burden while reinforcing patient trust and safeguarding brand reputation in an increasingly complex global market.